Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials

被引：0
|
作者：
Abel, M. K. [1 ]
Diaz, I. [2 ]
Levine, J. [3 ]
Pate, L. [3 ]
Viggiano, E. [3 ]
Melisko, M. [4 ]
Mukhtar, R. [2 ]
机构：
[1] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA
[3] Lobular Breast Canc Assoc, Patient Advocacy, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Med Hematol & Oncol, San Francisco, CA 94143 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
274
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [41] Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance
    Hutcheson, Laurie
    Axelrod, Janice
    Cushing, Tracy
    Fitzwater, Colleen
    Jeselsohn, Rinath
    Joergensen, Gitte
    Karsten, Maria
    Kimm, Miranda
    Kruse, Megan
    Langdon, Theresa
    Levine, Julia
    Mitchell-Daniels, Mason
    Mukhtar, Rita
    Neilsen, Barbara
    Paluch-Shimon, Shani
    Pross, Therese
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials
    Schreiber, Anna R.
    Kagihara, Jodi A.
    Weiss, Jennifer A.
    Nicklawsky, Andrew
    Gao, Dexiang
    Borges, Virginia F.
    Kabos, Peter
    Diamond, Jennifer R.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Phase II and III clinical trials of toremifene for metastatic breast cancer
    Vogel, CL
    ONCOLOGY-NEW YORK, 1998, 12 (03): : 9 - 13
  • [44] Economic impact of inclusion of women with metastatic breast cancer in clinical trials
    Voidey, A.
    Nerich, V.
    Essert, M.
    Rouillon, A. -F.
    Perrin, S.
    Limat, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 395 - 395
  • [45] Perceptions and needs of women with metastatic breast cancer: A focus on clinical trials
    Nahleh, Zeina A.
    Lin, Nancy U.
    Wolff, Antonio C.
    Cardoso, Fatima
    BREAST, 2013, 22 (03): : 370 - 373
  • [46] Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
    Nuzzolese, Imperia
    Montemurro, Filippo
    LANCET ONCOLOGY, 2020, 21 (01): : 21 - 24
  • [47] Systemic Therapy of Metastatic Breast Cancer: The Truth Beyond the Clinical Trials
    Gueth, Uwe
    Huang, Dorothy Jane
    Schoetzau, Andreas
    Holzgreve, Wolfgang
    Wight, Edward
    ONCOLOGY, 2009, 76 (04) : 247 - 253
  • [48] EVOLUTION AND LANDSCAPE OF CLINICAL TRIALS FOR BREAST CANCER PATIENTS
    Dogan, S.
    Goubar, A.
    Arnedos, M.
    Delaloge, S.
    Andre, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [49] Exclusion of Male Patients in Breast Cancer Clinical Trials
    Duma, Narjust
    Hoversten, Katherine P.
    Ruddy, Kathryn J.
    JNCI CANCER SPECTRUM, 2018, 2 (02)
  • [50] Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer
    Masayuki Inoue
    Hiroshi Nakagomi
    Haruka Nakada
    Kazushige Furuya
    Kou Ikegame
    Hideki Watanabe
    Masao Omata
    Toshio Oyama
    Breast Cancer, 2017, 24 : 667 - 672
12345